@WHO: Patients that benefit most from these therapeutics are those who are: 🔷non-severe and at higher risk for hospitalization 🔷severe or critical with seronegative status (have not developed antibodies against COVID-19) https://t.co/dXmYDVb7Mi https://t.co/KITwkAJXxU

@WHO: Patients that benefit most from these therapeutics are those who are: 🔷non-severe and at higher risk for hospitalization 🔷severe or critical with seronegative status (have not developed antibodies against COVID-19) https://t.co/dXmYDVb7Mi https://t.co/KITwkAJXxU

http://twitter.com/WHO
via IFTTT

Comments